Medtronic Starts U.S. Arm Of Global Study Comparing Safety Of Endeavor(R) And Cypher(R) Drug-Eluting Stents

Reflecting its ongoing commitment to patient safety and clinical research, Medtronic, Inc. (NYSE: MDT), announced the initiation of the first investigational sites in the United States to participate in PROTECT,1 the company’s global study comparing the Endeavor® and Cypher® drug-eluting stents on key safety metrics, including stent thrombosis - a rare but serious adverse event in which a blood clot forms inside the stent, with the potential to cause heart attack or death.

More: continued here

Filed under: Blood on August 11th, 2008